Dai Hailang, Jiao Yihang, Sun Zhangchi, Cao Zhuangqi, Chen Xianfeng
The State Key Laboratory on Fiber Optic Local Area Communication Networks and Advanced Optical Communication Systems, school of Physics and Astronomy, Shanghai JiaoTong University, Shanghai 200240, China.
Collaborative Innovation Center of IFSA (CICIFSA), Shanghai Jiao Tong University, Shanghai 200240, China.
Biomed Opt Express. 2018 Aug 7;9(9):4149-4161. doi: 10.1364/BOE.9.004149. eCollection 2018 Sep 1.
The timely discovery of cancer cell resistance in clinical processing and the accurate calculation of drug dosage to reduce and inhibit tumour growth factor in cancer patients are promising technologies in cancer therapy. Here, an optofluidic resonator effectively detects drug interactions with cancer cell processing in real time and enables the calculation of label-free drug-non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) and binding ratios using molecular fluorescence intensity. According to clinical test and in vivo experimental data, the efficiencies of gefitinib and erlotinib are only 37% and 12% compared to AZD9291, and 0.300 μg of EGFR inactivation requires 0.484 μg of AZD9291, 0.815 μg of gefitinib and 1.348 μg of erlotinib. Experimental results show that the present method allows for the performance detection of drug resistance and for the evaluation of dosage usage.
在临床治疗过程中及时发现癌细胞耐药性，并准确计算药物剂量以降低和抑制癌症患者的肿瘤生长因子，是癌症治疗中很有前景的技术。在此，一种光流体谐振器可有效实时检测药物与癌细胞治疗过程中的相互作用，并能够利用分子荧光强度计算无标记药物与非小细胞肺癌（NSCLC）表皮生长因子受体（EGFR）的结合比率。根据临床试验和体内实验数据，与AZD9291相比，吉非替尼和厄洛替尼的效率分别仅为37%和12%，且使0.300μg的EGFR失活需要0.484μg的AZD9291、0.815μg的吉非替尼和1.348μg的厄洛替尼。实验结果表明，本方法可用于耐药性的性能检测和剂量使用评估。
